CRAB is honored to partner with a diverse variety of university programs and research consortia. The benefits in these collaborations include continuity of service by experts in the disease site, ease in customization of systems for similar trials, unified data bases available for analyses, and reduced costs. Several of our long standing partnerships are - click a partner name below for more information.
Mesothelioma Applied Research Foundation
CRAB is honored to partner with the Mesothelioma Applied Research Foundation to establish the feasibility of using tumor volume measurement via computer tomography (CT) imaging (volumetric CT) in the clinical staging of malignant pleural mesothelioma (MPM). The Judith L. Lagana Memorial Grant will also determine the feasibility of developing a multicenter network to use volumetric CT scan as a uniform measurement of clinical T state in newly diagnosed MPM. Results from the study will inform larger international studies of tumor response assessment that will refine the radiological methods for this imaging modality in MPM. Successful implementation of volumetric CT imaging will have a direct widespread impact on the design of clinical trials and correlative studies in MPM.
International Association for the Study of Lung Cancer (IASLC)
CRAB has been an integral collaborator with the IASLC since the 1990s, and will continue this partnership through at least 2024. Under the leadership of IASLC, CRAB has gathered and analyzed data on nearly 200,000 lung cancer cases and conducted elegant analyses of the data, culminating over the years in two evidence-based revisions of the staging system for lung cancer. These revisions of the tumor, node, and metastasis (TNM) staging classification system for lung cancer were adopted by both the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC), in 2009 (7th edition) and 2017 (8th edition). We are now at work on the 9th edition, due in 2024. This partnership with IASLC has also resulted in a revision of the 8th edition guidelines for malignant pleural mesothelioma, based upon a collection of over 4,000 cases, as well as for thymic malignancies. These projects will continue through 2024 as well, informing the 9th edition staging criteria for these two less common thoracic malignancies.
The Myeloma Institute, at the University of Arkansas for Medical Sciences, continues to be an international leader for investigations in the treatment of multiple myeloma. The Myeloma Institute sees more patients with myeloma and related diseases per year than any other institution in the world, and CRAB’s partnership and scientific collaboration with the Myeloma Institute continues to deepen. CRAB’s contributions to the Myeloma Institute projects include experimental design, data acquisition and database development, statistical analysis, interpretation, and presentation of findings. Advances in the treatment of myeloma during this collaboration have included the use of thalidomide, the refinement of total therapy, the identification of prognostic markers and for the first time, the use of the word “cure” for this disease in 2010.
Pancreatic Cancer Research Team (PCRT)
Since 2003, our strategic partnership with PCRT has evolved and resulted in an expansion of CRAB’s role that now includes more broad support across most new PCRT projects. As the PCRT’s clinical trial program blossoms, CRAB is poised to grow this relationship and build upon the strong foundation we’ve established during the past decade. CRAB provides expanded clinical trial support for trials within the PCRT network, including both investigator-sponsored trials, as well as industry-sponsored projects. The services we provide for PCRT projects include statistical design and analysis, customization of an electronic data capture (EDC) solution, clinical monitoring, data management, and project oversight. Our experience with PCRT includes Phase I, I/II, and II clinical trials, support for the PCRT web portal infrastructure, and providing management and reporting for the ongoing PCRT Serum Bank project. With several new projects on the horizon, and a healthy pipeline of new opportunities, we envision this partnership continuing to expand well into the future.
International Myeloma Foundation (IMF)
CRAB’s collaboration with the International Myeloma Foundation (IMF) began in the 1990s. The newest projects include an investigation into the prognostic information in specific chromosomal abnormalities as an addition to the International Staging System introduced by CRAB and the IMF. We are also collaborating on a new project to gather historical data on patients treated at relapse with newer targeted agents, to serve as controls for future phase II studies.
CRAB Clinical Trials Consortium (CRAB CTC)
CRAB’s Clinical Trials Consortium (CRAB CTC) has grown to become a central resource for investigators, biopharmaceutical sponsors, non-profit foundations and others looking to develop novel cancer treatments for patients with lung cancer. 2010 was a landmark year for the CRAB CTC as we held our first annual investigator meeting, initiated our first clinical trial, and expanded our investigator membership. In the coming year, we expect to activate additional clinical trials, grow our leadership, and expand our geographical footprint. CRAB CTC is committed to providing objective expertise to support efficient drug development that makes a difference for patients. Additional information can be found at www.crabctc.org.